Institution Directory

Clinical trials at Vanderbilt University Medical Center

Sites in Nashville, TN

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 4:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1269

Shown on this page

Current sort

Live official records

Conditions: Sensorineural Hearing Loss, Bilateral
Interventions: Natural History Study; Other
Lead sponsor: Akouos, Inc.; Industry
Eligibility: Up to 44 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 4
States / cities: Iowa City, Iowa • Cincinnati, Ohio • Philadelphia, Pennsylvania + 1 more

Conditions: Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer
Interventions: HLX22, Pembrolizumab, Trastuzumab, Oxaliplatin, Capecitabine; Drug
Lead sponsor: Shanghai Henlius Biotech; Industry
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 29
States / cities: Anaheim, California • Los Alamitos, California • Greeley, Colorado + 24 more

Conditions: Cervical Spine Degeneration, ACDF Surgery
Interventions: Early PT, Delayed PT; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 4
States / cities: Honolulu, Hawaii • Nashville, Tennessee • Fort Sam Houston, Texas + 1 more

Conditions: Obesity, Hypertension
Interventions: Amlodipine, Moxonidine, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Tricuspid Valve Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases, Cardiovascular Diseases, Heart Failure
Interventions: Edwards EVOQUE System, Optimal Medical Therapy; Device · Drug
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: 18 Years and older
Enrollment: 864 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 55
States / cities: Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 41 more

Conditions: Asymptomatic
Interventions: Contrast-enhanced Magnetic Resonance Imaging, Digital Tomosynthesis Mammography, Quality-of-Life Assessment, Questionnaire Administration; Diagnostic Test · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 1,516 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2026
U.S. locations: 67
States / cities: Gilbert, Arizona • Pasadena, California • Denver, Colorado + 54 more

Conditions: Breast Cancer Female, Breast Cancer, Breast Cancer, Early-Onset, Breast Disease, Breast
Interventions: Robotic NSM, Open NSM; Device · Procedure
Lead sponsor: Intuitive Surgical; Industry
Eligibility: 21 Years and older · Female only
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 15
States / cities: Irvine, California • Los Angeles, California • Jacksonville, Florida + 12 more

Conditions: Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer, Hormone-Refractory Prostate Cancer
Interventions: GnRH agonist/antagonist, Prednisone, Abiraterone Acetate, Enzalutamide; Biological · Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2029
U.S. locations: 5
States / cities: Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 2 more

Conditions: Ductal Breast Carcinoma, Invasive Breast Carcinoma, Lobular Breast Carcinoma, Medullary Breast Carcinoma, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Tubular Breast Carcinoma
Interventions: Radiation Therapy, Questionnaire Administration, Quality-of-Life Assessment, Laboratory Biomarker Analysis, Hypofractionated Radiation Therapy; Radiation · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 898 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2035
U.S. locations: 846
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 544 more

Conditions: Carcinoma, Squamous Cell, Oral Cancer, Oropharynx Cancer, Larynx Cancer, Lip Cancer, Esophageal Cancer
Interventions: Durvalumab, Carboplatin, Nab-paclitaxel, Cisplatin, Surgical resection, IMRT; Drug · Procedure · Radiation
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Nashville, Tennessee

Conditions: ARDS, Sepsis, Pneumonia
Interventions: Blood collection, Urine Collection, Nasal, oral, and rectal swabs, Stool collection, Heat Moisture Exchange Filter collection, Tracheal Aspirate sample collection, Non-bronchoscopic bronchoalveolar lavage (NBBAL), Surveys, Short physical performance battery, Hand grip strength, CNS Vital Signs, Muscle Ultrasound, Muscle Strength, Spirometry, Lung Diffusion Testing (DLCO), Chest CT Scan; Other · Procedure · Radiation
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 20
States / cities: Fresno, California • Palo Alto, California • San Francisco, California + 12 more

Conditions: Empyema, Pleural, Pleural Infection
Interventions: Saline Flush; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 5
States / cities: Sterling Heights, Michigan • Omaha, Nebraska • New York, New York + 2 more

About this Vanderbilt University Medical Center institution page

What this page lists: ClinicalTrials.gov records that list Vanderbilt University Medical Center in Nashville, TN as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Vanderbilt University Medical Center

Filter and sort this campus

Live official records

Otoferlin Gene-mediated Hearing Loss Natural History Study

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

Function After Anterior Cervical Discectomy and Fusion Surgery: Timing of Physical Therapy

Sympathetic Mechanisms in Obesity-Crossover Design

TRISCEND II Pivotal Trial

Abbreviated Breast MRI and Digital Tomosynthesis Mammography in Screening Women With Dense Breasts

Robotic vs. Open NSM for Early Stage Breast Cancer

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

The APS Phenotyping Study

Chest Drain Regular Flushing in Complicated Parapneumonic Effusions and Empyemas

About this Vanderbilt University Medical Center institution page